Abstracts tagged "nephritis and plasma cells"

Abstract Number: 1779 • 2018 ACR/ARHP Annual Meeting
Is the Number of IgG4+ Plasma Cells Observed By Immunostaining Important Beyond Its Diagnostic Utility in IgG4-Related Disease?
Eduardo Martín Nares¹, Jacobo Guerrero Castillo², Arturo Angeles Angeles² and Gabriela Hernandez-Molina¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Pathology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: The histopathological findings in IgG4-related disease (IgG4-RD) includes the presence of dense lymphoplasmacytic infiltrate, obliterative phlebitis, storiform fibrosis and the presence of marked IgG4+…
Abstract Number: 2890 • 2013 ACR/ARHP Annual Meeting
Novel Selective Inhibitors Of Nuclear Export (SINE) Decrease Type I Interferon Activation and Deplete Autoreactive Plasma Cells In The Kidney In Murine Lupus
Teresa Owen¹, Javier Rangel-Moreno², Boris Klebanov³, Yosef Landesman³, Michael Kauffman³, Sharon Shacham³ and Jennifer H. Anolik⁴, ¹Medicine- Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Medicine- Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, ³Karyopharm Therapeutics Inc., Natick, MA, ⁴Medicine- Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose: There is great interest in developing new treatment approaches for SLE, but the biologic therapies under investigation over the past several years have yielded…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].